TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has completed enrollment for a U.S. Phase IIa study of its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30, aimed at treating obesity. This milestone marks significant progress in the development of ASC30, which has demonstrated a 46-day half-life, supporting its potential as a once-monthly treatment option. Topline data from this study are expected in the first quarter of 2026, potentially impacting the company’s market positioning in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative therapies, particularly in the field of obesity treatment. The company is known for its proprietary Ultra-Long-Acting Platform (ULAP) technology, which supports the development of long-acting treatment formulations.
Average Trading Volume: 9,437,429
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.08B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.